AstraZeneca, Forest Enter Superbug Combo In Late Stage Trials

Date : 10/18/2011 @ 11:28AM
Source : Dow Jones News
Stock : Forest Laboratories Inc. (FRX)
Quote : 99.0  0.0 (0.00%) @ 2:05AM

AstraZeneca, Forest Enter Superbug Combo In Late Stage Trials

Astrazeneca (NYSE:AZN)
Historical Stock Chart

5 Years : From Jan 2013 to Jan 2018

Click Here for more Astrazeneca Charts.

U.K.-based AstraZeneca PLC (AZN) and U.S. partner Forest Laboratories Inc. (FRX) Tuesday said they plan a late-stage clinical trial program to investigate a combination antibiotic against superbug infections.

The two drug makers will enter ceftazidime/avibactam into five Phase 3 trials to show the combination is an effective and well-tolerated treatment for patients with Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections.

"This combination of a broad-spectrum cephalosporin and a novel beta-lactamase inhibitor has the potential to be effective against bacteria that would otherwise be resistant to antibiotics in patients suffering from serious and potentially life-threatening infections," Marco Taglietti, president of Forest Research Institute, said in a statement.

The partners said they aimed to submit ceftazidime/avibactam for regulatory approval in 2014.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292;

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.